Secretary of Health and Human Services Robert F. Kennedy Jr.
The Associated Press
Kenvue Faces Backlash Amid Unfounded Autism Claims Surrounding Tylenol: What’s Next for RFK Jr.?
Tylenol could just be the tip of the iceberg.
For years, Robert F. Kennedy Jr. has voiced strong objections to a plethora of medications and health measures, often making sweeping claims without scientific backing. His assertions range from Tylenol causing autism to Ozempic leading to suicidal ideation. Now, as the Secretary of Health and Human Services under President Trump, Kennedy is transforming these controversial views into actual public policy. His “Make America Healthy Again” initiative is already affecting vaccine accessibility for COVID-19 and propagating dubious assertions about Tylenol. But what else can we anticipate from his administration?
In a recent letter written with FDA Commissioner Marty Makary, Kennedy informed 22 Republican attorneys general that the FDA is currently investigating the safety of mifepristone, the medication used in approximately two-thirds of all medical abortions. If restrictions are placed on this medication, it could drastically reduce access to abortion services across the country.
Antidepressants also loom large on Kennedy’s radar. During his confirmation hearings, he falsely claimed that discontinuing serotonin-based antidepressants was more difficult than quitting heroin. His statements also suggested that adolescents using these medications are at a heightened risk of committing school shootings, a claim that lacks credible evidence (they aren’t).
Kennedy’s “Make America Healthy Again” initiative clearly outlines one of its objectives: to “assess the prevalence and risks associated with the prescribing of selective serotonin reuptake inhibitors.” Any moves to impose restrictions on these medications could lead to severe ramifications for the 11% of the American population that relies on them to manage mental health issues such as depression and anxiety (11% of the population).
Another frequent target of Kennedy’s rhetoric is statins, which are prescribed to over 92 million Americans for cholesterol management and heart disease prevention. Most studies affirm that statins are effective and mitigate serious heart disease risks, the leading cause of death in the United States.
Nevertheless, Children’s Health Defense, the organization founded by Kennedy, has published articles questioning the correlation between cholesterol levels and heart disease. One such article branded them “overprescribed and unnecessary.” Earlier this year, Kennedy claimed in a podcast that pharmaceutical companies manipulated studies to substantiate the efficacy of statins.
Among the goals of Kennedy’s initiative is to scrutinize the use of selective serotonin reuptake inhibitors. Restrictions on their usage would be a serious concern for millions of Americans who rely on these treatments.
Kennedy also targets newer drug classes, such as GLP-1s, which are growing in popularity for treating diabetes (Ozempic, Mounjaro) and obesity (Wegovy, Zepbound). Despite their effectiveness and potential roles in treating various health issues, including sleep apnea and drug addiction, he has criticized their costs and spread misinformation about their marketing practices. For example, he falsely claimed that the manufacturer Novo Nordisk sells Ozempic exclusively in the U.S.
In a crucial first step against their usage, Kennedy turned down a proposal that would have allowed Medicare to cover GLP-1 drugs for obesity, limiting access for 7 million additional Americans. Currently, Medicare does cover these treatments for diabetes.
Kennedy made a controversial statement regarding these medications, claiming, “They’re counting on selling it to Americans because we’re so stupid and so addicted to drugs,” referring to Novo Nordisk and their product, Ozempic. His views on such matters raise questions about the direction of health policy under his leadership.
It remains to be seen what kind of changes will occur as Kennedy continues his campaign against widely used medications and therapies.
MORE FROM FORBES
ForbesTrump’s Unproven Claims About Tylenol And Autism Are Reaching Millions On TikTokBy Emily Baker-White
ForbesRFK Jr.’s CDC Is Poised To Restrict Vaccines Even FurtherBy Alex Knapp
ForbesThis Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug PricingBy Amy Feldman
